The PCL-C had diagnostic utility in screening mothers of childhood cancer survivors. The presence of comorbid diagnoses such as anxiety and depression should be examined.

The results of this study were partially consistent with Creamer's cognitive processing theory. A moderating effect was found for disease stage on associations between intrusions, avoidance, physical impairment, and distress.

We describe the case report of a 56 year old woman with no prior psychiatric history who was diagnosed with hormone receptor positive early stage breast cancer and who developed severe mood changes after administration of anastrozole which resolved after discontinuation of treatment. Aromatase inhibitors are the preferred hormonal approach for postmenopausal women with estrogen hormone sensitive breast cancer. The third-generation agents (anastrozole, letrozole and exemestane) have been shown to be more effective and safe than the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifen. Treatment strategies with these agents include the use of an aromatase inhibitor as an upfront strategy for 5 years, as a sequential approach after 2-3 years of tamoxifen, or as extended use after the classical 5 years of tamoxifen.The side effects of aromatase inhibitors, as compared with selective estrogen receptor modulators, are different, reflecting the specific mechanism of action of these drugs. Aromatase inhibitors are well tolerated and cause a lower incidence of gynecological symptoms (vaginal bleeding, discharge and endometrial neoplasia), venous thromboembolic events and hot flashes compared with tamoxifen. However the use of aromatase inhibitors has been associated with loss of bone density, arthralgia, myalgia, a negative effect on lipid metabolism and cardiovascular risk (Tomao et al., 2008). Mood disturbances, somnolence, anxiety, fatigue, hot flashes, and memory impairment have been reported among patients receiving anastrozole as adjuvant therapy.